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The Experience of Fatigue and Quality of Life in Patients with Advanced Lung 
Cancer 
 
Andrea Shaffer 
ABSTRACT 
Fatigue is the most prevalent and distressing symptom experienced by 
patients with advanced lung cancer and especially among those patients 
undergoing therapy.  Advanced lung cancer and its associated symptoms can 
significantly impact the quality of life (QOL) of those who have the disease.   The 
primary purpose of this study was to measure fatigue levels, characterize the 
fatigue experience, and assess for gender differences in perceptions of fatigue 
and QOL in patients with advanced lung cancer receiving chemotherapy.  The 
secondary purpose of the study was to examine practice patterns in the 
ambulatory setting regarding the routine assessment of fatigue. 
The study was a secondary analysis of a larger study being conducted in 
the ambulatory clinics of a large, National Cancer Institute-designated 
comprehensive cancer center.  The study sample consisted of fifty advanced 
lung cancer patients, 25 men and 25 women.  Two self-report questionnaires, the 
Short-Form 36® (SF-36) Acute Version 1 and Fatigue Symptom Inventory (FSI), 
were completed by the subjects after receiving a single cycle of chemotherapy.  
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A chart audit of the 50 subjects was performed assessing for provider 
documentation of fatigue assessment and method(s) utilized. 
Subjects ranged in age from 40 to 80, with a mean age of 62.4 years.  Of 
the 50, 26 patients had Stage IV non-small cell lung cancer.  A majority of the 
patients were receiving chemotherapy alone and had not received prior 
chemotherapy.   
The results of this study revealed no significant gender differences in 
fatigue severity, frequency, or interference levels.  The study results also failed to 
confirm gender differences in QOL measures.  The chart audit did reveal that the 
providers in this study did not consistently assess and document fatigue levels, 
with the nurses documenting less frequently than the physicians.    
The results of this study did suggest that fatigue levels and QOL are 
problematic for patients treated for lung cancer.  In an effort to better assist 
patients and tailor plans of care, it is vital that practitioners, especially nurses, 
assess for fatigue in advanced lung cancer patients.    
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Chapter One 
Introduction 
Fatigue is a symptom that every person will experience at least once, but 
usually multiple times during his or her life.  In the healthy person, fatigue begins 
when the individual physically exerts, experiences stress, or lack of sleep, and 
serves as a protective function by signaling the person to restore energy by 
resting.  A good night’s sleep or a few hours of relaxation will generally revive a 
healthy individual to a normal level of functioning (Yarbro, Frogge, & Goodman, 
2005).  Fatigue as a result of cancer and its treatments differs from acute fatigue 
because patients continue to suffer feelings of weakness and tiredness despite 
rest (Byar et al., 2006). 
Fatigue is the most prevalent and distressing symptom experienced by 
patients with cancer and undergoing therapy.  Individuals with cancer were the 
first to call fatigue a cancer-related symptom.  It is estimated that fatigue is 
reported by 60 to 100 percent of individuals with cancer during their course of 
disease and associated treatment (Yarbro et al., 2005).  This symptom affects 70 
to 95 percent of patients receiving chemotherapy, radiation therapy, or 
biotherapy and lingers in 17 to 40 percent of disease-free cancer survivors 
(Lavdaniti et al., 2006). 
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Fatigue is a multidimensional, subjective experience with physiologic, 
psychological, functional, and social consequences (Donovan & Ward, 2005).  
The etiology of fatigue is multifactorial in that it may be related to the disease 
itself, to sleep disturbance, to concurrent systemic issues such as anemia or 
pain, or to emotional distress (Madden & Newton, 2006).  Fatigue is 
characterized by subjective signs such as feelings of tiredness, muscle 
weakness, negative mood, loss of alertness, and the perception of interference 
with daily living activities (Madden & Newton, 2006; Yarbro et al., 2005).  The 
objective manifestations of fatigue can include weight loss, decreased energy, 
apathy, anemia, weakness, lack of motivation, decreased attention, excessive 
sleepiness, or alterations in sleep patterns (Yarbro, et al., 2005).  Fatigue varies 
in unpleasantness, duration and intensity (Byar et al., 2006). 
Lung cancer is the second most common cancer diagnosis and is the 
leading cause of cancer mortality worldwide.  In the United States, the five-year 
survival rate across all stages of lung cancer remains at approximately 14% and 
has not changed significantly in several decades.  The most common symptoms 
reported by newly diagnosed lung cancer patients at any stage and for those 
undergoing therapy for advanced disease are fatigue along with pain, anorexia, 
insomnia, cough and dyspnea (Tanaka et al., 2002).  Given this information, it is 
vital to improve the quality of life in this patient population and affect the single 
most common symptom experienced.   
Quality of life (QOL) is a multidimensional phenomenon that can often be 
impacted by the experience of living with lung cancer.  Lung cancer can 
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positively or negatively influence the physical, social, psychological, and spiritual 
dimensions of daily living.  Patients with lung cancer report the greatest amount 
of psychological stress in comparison with other cancer patients.  Disturbances in 
QOL are vital to assess during the entire disease continuum (Sarna et al., 2005). 
Lung cancer and its associated symptoms have a significant impact on 
quality of life of those who have the disease.  However, there has been little 
research about how gender affects the symptom experience of people with lung 
cancer (Hoffman et al., 2007).  According to the Centers for Disease Control and 
Prevention (2007), lung cancer is the second most common cancer among white, 
black, Asian/Pacific Islander, American Indian/Alaska Native, and Hispanic men.  
Lung cancer is the second most common cancer among white and American 
Indian/Alaska Native women in the United States, and mortality rates in women 
are nearly twice that of breast cancer.  Lung cancer death rates for U.S. women 
are among the highest in the world.  There has been a progressive swing in lung 
cancer demographics with a significant increase in women patients in the last two 
decades (Loevgren et al., 2007).   
Fu and colleagues (2005) sought to further characterize the effect of 
gender on the clinical features and survival patterns of patients with lung cancer 
by analyzing data collected from the National Surveillance, Epidemiology, and 
End Results Database (SEER).  They found that women were diagnosed at an 
earlier age than men, raising the question of gender-specific differences in 
susceptibility to carcinogens.  However, women statistically have better 
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outcomes than men at all stages of disease possibly because of hormonal 
influences. 
Despite the fact that the demographics of lung cancer are changing from a 
predominantly male disease, most studies of symptoms and/or quality of life 
(QOL) are based on Caucasian, middle-income men with advanced lung cancer.  
Some studies have suggested that the symptom experiences of men and women 
with lung cancer are different and that women report more and a greater intensity 
of symptoms than men (Loevgren et al., 2007).  Also, role differences often exist 
between men and women, which could significantly impact the perception of 
intensity of symptoms and greatly affect quality of life. 
At the 2007 Oncology Nursing Society 32nd Annual Congress, attendees 
for a special symposium entitled “Cancer-Related Fatigue:  The 6th Vital Sign” 
were surveyed about practice patterns in their particular settings and about their 
experience in assessing cancer-related fatigue (CRF).  The results revealed that 
approximately one-third of patients with cancer may not be routinely assessed for 
fatigue and of those who are assessed for CRF, likely only half of the acquired 
information is being documented.  The nurses cited barriers to routine 
assessment of this symptom in their practices as time constraints, lack of an 
appropriate assessment tool, and lack of an appropriate documentation tool 
(Given, 2008).  
Statement of Problem 
An increasing amount of research is available documenting the 
experience of fatigue and its effect on quality of life in women with breast cancer 
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during treatment and in survival phases.  Few studies exist that have examined 
potential gender differences in the experience of fatigue and perceived impact on 
QOL in patients with advanced lung cancer receiving chemotherapy.  As the goal 
of palliative chemotherapy is symptom control and a majority of lung cancers are 
diagnosed in advanced stages, it is imperative that the extent and significance of 
the fatigue experience be further defined.  The primary purpose of this study was 
to measure fatigue levels, characterize the fatigue experience, and assess for 
gender differences in perceptions of fatigue and QOL in patients with advanced 
lung cancer receiving chemotherapy.  The secondary purpose of this study was 
to examine practice patterns in the ambulatory setting regarding the routine 
assessment of fatigue.  As fatigue is identified as a prevalent and distressing 
issue in cancer populations, it is important that clinicians are assessing for 
fatigue and determining to what extent it may be affecting overall quality of life. 
Research Questions 
1.  What are the reported fatigue levels in advanced lung cancer patients who 
have received a single cycle of chemotherapy?  
2.  Are there gender differences in the severity, frequency, and total interference 
of the fatigue experience? 
3.  Are there gender differences in quality of life in advanced lung cancer 
patients?  
4.  How often are providers assessing lung cancer patients for fatigue and 
documenting information obtained?  
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5.  Which method(s) are utilized to perform fatigue assessment in lung cancer 
patients? 
Definition of Terms 
 For the purposes of this study, fatigue and QOL are defined as: 
1.  Fatigue is a multidimensional concept that includes physical, psychological, 
social and spiritual aspects and is characterized by feelings of weakness and 
tiredness not fully relieved by rest (Byar et al., 2006). 
2.  Quality of life is defined as a multidimensional, intricate concept that blends 
the physical, functional, psychological, and social well-being of each individual.  
(Losito et al., 2006). 
Significance to Nursing 
Fatigue is a very important concept for healthcare professionals to 
examine and attempt to understand.  Fatigue is a problem that can lead to other 
physiologic and psychologic symptoms that collectively affect every aspect of a 
patient’s life and thereby impact overall QOL.   Studies have already indicated 
gender differences in survival rate and susceptibility in people with lung cancer.  
Few studies have defined gender differences in the symptom experiences of 
people with lung cancer (Hoffman et al., 2007).  Therefore, it is important to 
elucidate this information as a first step in tailoring interventions to the particular 
needs of the defined population.  The assessment and documentation of fatigue 
levels and recommended management techniques by practitioners is vital to 
making an impact on this very distressing cancer-related symptom. 
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Chapter Two 
Review of Literature 
Fatigue is the most frequently reported symptom experienced by patients 
with cancer across the disease continuum.  Fatigue is distressing, greatly 
impacts quality of life, and profoundly effects patients’ abilities to function in 
routine roles and activities.  The severity of the fatigue experience can delay 
treatments, persist for months or years, and may be predictive of shorter survival 
in particular cancer populations (Beck, Dudley & Barsevick, 2005).  Hoffman et 
al. (2007) noted that few studies have targeted gender differences in the 
symptom experiences of patients with lung cancer, and the results of the studies 
have been mixed.   
Quality of Life and Fatigue 
In 2001, Okuyama et al. conducted a study to determine the prevalence of 
interference of daily activity due to fatigue in advanced lung cancer patients, the 
correlated factors, and methods to detect at risk patients.  The study accrued 157 
subjects with advanced stage or recurrent disease, of which the majority were 
male, from ambulatory patients at two large academic centers in Japan.   
The researchers utilized several instruments to ascertain the information 
they were seeking including the Cancer Fatigue Scale (CFS), the Fatigue 
Numerical Scale (FNS), and a self-administered questionnaire asking if fatigue 
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had interfered with any of seven domains of their activities of daily living.  The 
CFS is a 15-item self-rating scale for assessing fatigue in cancer patients that 
consists of three subscales and is modeled to assess the multi-dimensional 
nature of fatigue.  Items are rated on a Likert-type scale with higher scores 
indicating more severe fatigue.  The FNS is a simplistic tool utilized for assessing 
fatigue intensity and patients rate their fatigue experience on an 11-point scale.  
The investigators also assessed a broad range of biopsychological factors, 
including cancer information and previous history of anti-cancer therapy, 
psychological distress, and demographical and social support status using 
medical record data, a self-administered questionnaire, and structured interview 
(Okuyama et al., 2001). 
The investigators found that 81.5% of patients experienced some degree 
of fatigue and that one-third of patients reported that fatigue had interfered with 
physical activities such as walking or normal work.  One fifth of the patients 
reported that fatigue had interfered with emotional activities such as mood or 
enjoyment of life and half of the patients were found to have clinical fatigue.  
Depression was also found to be a correlated factor for fatigue (Okuyama et al., 
2001).  Limitations of this study are the lack of gender representation and 
therefore, lack of ability to generalize results to entire population of advanced 
lung cancer patients. 
Tanaka and colleagues (2002) investigated how often fatigue, dyspnea, 
and pain interfered with daily living activities, whether any differences existed in 
the characteristics of these symptoms regarding impact on daily life activities, 
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and whether an 11-point numerical scale was appropriate for screening for those 
symptoms interfering with at least one daily life activity in ambulatory patients 
with advanced lung cancer.  The study accrued 171 patients and again a majority 
of the patients were male.  Subjects were recruited from ambulatory lung cancer 
clinics in two large academic centers in Japan. 
The researchers utilized a questionnaire to be completed by the subjects 
at home and then returned in the mail.  If any items were left blank, telephone 
inquiry was used to obtain missing data.  The severity of dyspnea, pain, and 
fatigue were evaluated with an 11-point numerical scale with the higher the rating 
correlating with a greater symptom distress.  Another questionnaire, which was a 
modified version of the Brief Fatigue Inventory (BFI), was used to assess the 
impact of the three symptoms on daily living activities in the previous 24 hours.  
The responses were either “presence” or “absence” of interference.  
Demographic information and medical information were obtained from medical 
record review (Tanaka et al., 2002).   
The investigators found that fatigue interfered with at least one daily life 
activity in 52% of subjects and mood and enjoyment were disturbed in 
approximately 20% with fatigue rated as severe as a seven.  Dyspnea interfered 
with at least one daily life activity in 55% of subjects, but subjects did not 
experience as significant a disturbance in mood and enjoyment.  Limitations of 
the study were that 74% of subjects had an Eastern Cooperative Oncology 
Group Performance Status (ECOG PS) of one, which is slightly higher than most 
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patients in this population, and the tools utilized were not properly validated and 
confirmed (Tanaka et al., 2002). 
Brown, McMillan, and Milroy in 2005 sought to explore the relationship 
between fatigue, physical function, the systemic inflammatory response, and 
psychological distress in patients with advanced lung cancer.  The study accrued 
a total of 55 patients, 38 lung cancer patients and 15 healthy subjects.  Of the 38 
lung cancer patients, 23 were men and 15 were women.  The lung cancer 
patients were those diagnosed with locally advanced or metastatic disease and 
recruited from two specialty palliative care centers and an associated hospital in 
the United Kingdom.  The healthy volunteers were age-matched and gender-
matched. 
The control group and patient group were assessed for fatigue, weakness, 
anthropometry, physical function, and psychological distress and several 
questionnaires were utilized to assess fatigue, weakness, and psychological 
distress.  The authors used the Functional Assessment of Chronic Illness 
Therapy-Fatigue scale (FACIT-F) to measure fatigue and this tool is a 13-item 
subscale of the FACIT-F questionnaire that has subjects score each item on a 
zero to four scale (not at all to very much).  A low total score represents a high 
level of fatigue.  The subscale assesses quality of life in cancer patients 
experiencing fatigue and other anemia-related symptoms.  Weakness was 
measured using a simple 10-cm visual analogue scale which ranged from “I don’t 
feel weak at all” to “I couldn’t feel any weaker”.  Psychological distress was 
measured using the Hospital Anxiety and Depression (HAD) scale and this is a 
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14-item self-report questionnaire intended to measure anxiety and depression.  
The subjects were asked to score the answer that came closest to how they had 
been feeling in the previous week on a scale of zero to three with a higher score 
suggestive of psychological distress (Brown, McMillan & Milroy, 2005). 
The results revealed that patients with advanced lung cancer had higher 
levels of weakness and fatigue and increased psychological distress as 
compared to the control group.  The authors subdivided the group of cancer 
patients on the basis of fatigue and found that fatigue was clearly associated with 
poor physical function and more psychological distress (Brown, McMillan & 
Milroy, 2005).  The comparison to the healthy population was interesting, 
however, likely not necessary as it is intuitive that the cancer population will 
report more symptoms and higher severity scores.  
Dagnelie and colleagues.  (2007) conducted a cross-sectional study to 
quantify the impact of fatigue, relative to other QOL domains, on overall QOL in 
lung and breast cancer patients preceding curative radiotherapy.  Their interest 
derived from lack of studies on this issue.  The study accrued a total of 64 
patients with 100% of the breast cancer patients being women and 45% of the 
lung cancer patients being women.  
The investigators used the European Organization for Research and 
Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) which is a 
30-item cancer-specific core questionnaire that contains five function subscales, 
three symptom subscales, and two single items assessing global health and 
“overall” QOL, and a number of single items addressing various symptoms and 
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believed financial impact.  Subjects were asked to complete the EORTC QLQ-
C30, as well as a demographic profile, prior to beginning radiotherapy (Dagnelie 
et al., 2007). 
The investigators found that EORTC QLQ-C30 scores revealed 
considerable impairment in global health status and overall QOL, especially in 
lung cancer patients.  Also, significant impairment was noted for the subscales 
physical, role and emotional functioning, and for the symptom subscales fatigue, 
dyspnea, pain, insomnia, and appetite loss.  Lung cancer patients reported being 
significantly more tired than breast cancer patients.  There was a distinct 
correlation between level of fatigue and perceived overall QOL (Dagnelie et al., 
2007).  A limitation of this study is the inability to generalize these results into 
advanced stages of lung cancer as the subjects in this trial were receiving 
curative radiotherapy. 
Bozcuk and colleagues in 2006 were interested in exploring disease and 
treatment factors that can affect QOL that have not previously been thoroughly 
investigated in patients with metastatic non-small cell lung cancer receiving 
chemotherapy.  The study acquired 50 patients with 46 men and only 4 women.  
Thirty-seven of the patients were receiving first line chemotherapy and thirteen 
were receiving second line.  All subjects had either unresectable stage three or 
stage four disease and were seen in ambulatory medical oncology clinics.   
The authors also utilized the EORTC QLQ-C30 questionnaire to assess 
the various aspects of QOL.  The questionnaire was completed prior to the first 
cycle, on day seven, and after the completion of the second cycle.  The 
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investigators gathered demographic, disease, and treatment data from medical 
record review (Bozcuk et al., 2006). 
The study results proved quite interesting.  The authors found that 
baseline QOL affects the change in QOL on chemotherapy in that those patients 
with a starting global QOL score less than or equal to 50 saw an increase in 
global QOL and physical functioning and a decrease in fatigue after two cycles of 
chemotherapy.  Conversely, those patients with a starting global QOL score 
greater than 50 saw a decline in global QOL and physical functioning, but an 
increase in fatigue.  Also, patients receiving second line chemotherapy reported 
less fatigue while on chemotherapy than those patients receiving first line 
chemotherapy (Bozcuk et al., 2006).  A definite limitation of this study was the 
few number of women represented in the study sample.    
Gender and Fatigue 
Sarna and Brecht (1997) performed an exploratory study, combining two 
studies of women with advanced lung cancer, with the purpose of investigating 
the underlying cluster of distressing symptoms experienced by women with 
advanced lung cancer and exploring the differences in symptoms among clinical 
and demographic variables.  The study looked at a combined total of 60 women 
accrued in oncology clinics, private practices, and oncology units.  Forty were 
from a previous descriptive study looking at women with any stage of disease 
and twenty were from a current longitudinal trial looking at women with advanced 
stage lung cancer.  The authors performed a secondary analysis of the forty 
women from the previous study.  The women ranged in age from 33 to 80 years, 
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were eight-seven percent Caucasian, the majority were married and had non-
small cell lung cancer in advanced stages. 
The Symptoms Distress Scale (SDS) is a 10-item self-report scale 
developed for assessing cancer-related symptoms, but for this study was 
modified to include 13 items pertinent to lung cancer patients.  Items are reported 
on a Likert-type scale with rates from one to five and five represents the most 
distress.  Clinical variables assessed included physical function, presence and 
mode of treatment, presence of distant metastases, smoking status, and 
presence of comorbid disease which was obtained from Karnofsky Performance 
Status rating and medical record data.  Demographic variables included race or 
ethnicity, age, marital status, employment status, income, and education which 
were collected from a demographic form completed by the patients (Sarna & 
Brecht, 1997). 
Sarna and Brecht (1997) found that fatigue, negative outlook, frequent 
pain, and insomnia were the most prevalent and the most seriously rated 
symptoms.  There were no differences reported in symptom distress by the 
presence of distant metastases, comorbid disease, histologic type of lung cancer, 
marital status, education, income, or smoking status.  Limitations of this study 
were small sample size in that essentially only 20 women were actively evaluated 
by the study instrument and lack of comparison of women to men to ascertain 
whether there were gender differences in symptom experience. 
Sarna et al. in 2005 conducted a prospective, cross-sectional, descriptive 
study to describe the quality of life (QOL) in women living with non-small cell lung 
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cancer, describe the characteristics of meaning of illness (MOI), and explore the 
demographic, clinical, health status, and MOI correlates of QOL.  The study 
collected data from 217 women, predominantly Caucasian, recruited from 
multiple clinical sites in the western, eastern, and southern regions of the United 
States.  All study participants had been diagnosed at least six months and less 
than five years with non-small cell lung cancer. 
The investigators utilized several instruments including the QOL Scale-
Patient Version (QOL-Patient) and the Short Form-36 Item (SF-36).  The QOL-
Patient is a 41-item questionnaire that was used in this study as a cancer-specific 
measure of QOL.  Each item uses a Likert-type scale on an 11-point range and 
consists of four subscales addressing physical, social, psychological, and 
spiritual well-being.  Subjects responded to questions based on how their cancer 
experience affected their quality of life.  The SF-36 was used as a generic 
measure of health-related QOL and is a 36-item self-report questionnaire that 
evaluates physical functioning, bodily pain, role limitations caused by physical 
health, role limitations caused by emotional health, emotional well-being, social 
functioning, vitality and fatigue, and general health perceptions.  Scores range 
from 0 to 100 one each subscale and higher scores indicate better QOL.  
Meaning of illness (MOI) was assessed using eight cards with individual 
statements describing illness in positive or negative terms.  All eight cards were 
placed in front of the subject at one time and the subject was asked to choose 
the card the most represented her view of her illness.  The investigators also 
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collected data on health status, depressed mood, demographics, and clinical 
variables (Sarna et al., 2005). 
The researchers found that women reported serious levels of fatigue, 
substantial disruptions in psychological well-being, and a strong relationship 
between health status and physical QOL.  One limitation of the study was that of 
the 217 subjects accrued, 184 were Caucasian, thereby making it difficult to 
generalize to all the population of women with lung cancer.  The investigators did 
only include those subjects with non-small cell lung cancer; however, this is of 
little consequence as the majority of patients with lung cancer have this histologic 
type (Sarna et al., 2005).  
Hoffman et al.  (2007) studied the relationships among pain, fatigue, 
insomnia, and gender while controlling for age, comorbidities, and stage of 
cancer.  The study was a secondary analysis of a single-blinded, randomized 
clinical trial of people with cancer sponsored by the National Cancer Institute and 
the National Institute for Nursing Research and the researchers selected only 
data on lung cancer patients obtained from the first interview at the time of entry 
into the trial.   
Participants were accrued from two community oncology programs and 
two comprehensive cancer centers.  The analysis was completed on 80 patients 
ranging from age 41 to 83 years and mostly married Caucasians.  The analysis 
was divided nearly even at 55% men and 45% women (Hoffman et al., 2007). 
The participants were exposed to a 10-session nursing intervention that 
lasted 20 weeks.  Symptoms were assessed utilizing the Cancer Symptom 
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Experience Inventory which is a self-report instrument of 15 symptoms related to 
cancer or its treatment.  For this study, the variable assessing the frequency of 
fatigue, pain, and insomnia was dichotomized to measure the duration of the 
relationships among fatigue, pain, and insomnia in people with a new diagnosis 
of lung cancer with 56 days of receiving chemotherapy.  Symptoms were rated 
on a scale from 0 to 10 with 10 indicating the greatest severity.  Comorbidities 
were assessed using a modified version of the Comorbidity Questionnaire which 
assessed for the presence or absence of 14 various chronic health conditions 
(Hoffman et al., 2007). 
The investigators found that there were no gender differences in fatigue 
reporting, with 98% of men reporting fatigue and 94% of women reporting 
fatigue.  Of the three symptoms of interest to the authors, the only symptom 
reported with higher levels of severity for women than men was insomnia.  
Limitations of this study were that it was a secondary analysis and that it was 
difficult to ascertain whether the symptoms addressed were related to disease 
and treatment or to comorbidities (Hoffman et al., 2007). 
Husain et al. in 2007 explored sex differences in fatigue at the end of life.  
The investigators hypothesized that a sex difference in fatigue exists and that 
sex-specific correlates lie beneath this difference.  The study was a three-month 
longitudinal study that accrued subjects from a home palliative care program 
serving a major urban center.  Patients had to be admitted to the palliative care 
program to be eligible to participate and were excluded if under the age of 18 and 
if cognitively impaired. 
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The study accrued a total of 102 patients with a fairly equal representation 
of each sex - 47 men and 55 women.  The participants completed questionnaires 
at zero, one, three, five, seven, nine, and eleven weeks and the disposition of 
patients were followed for 12 months after completion of the study.  The 
investigators utilized the Brief Fatigue Inventory (BFI) which is a nine-item, self-
report, symptom severity and functional interference scale.  The tool measures 
the single domain of fatigue severity and a score of greater than 3 was used as a 
discontinuance point to identify moderate to severe fatigue.  The investigators 
also utilized the McGill Quality of Life (MQOL) Questionnaire which is a 
multidimensional tool that measures physical, psychological, support, and 
existential domains.  Scores are reported from 0 to 10 and higher scores 
correlate with better QOL (Husain et al., 2007). 
The authors of the study found that the prevalence of moderate to severe 
fatigue at week zero and over time was significantly higher in women than in 
men.  Interestingly, no differences in MQOL scores were found between the 
sexes.  This study was the first such study documenting that women experience 
a higher prevalence of fatigue and a marked fatigue severity, at least in the 
setting of advanced illness receiving palliative care at home.  A limitation of this 
study was that it did not elucidate specific cancer diagnosis and therefore, did not 
account for specific cancer treatments (Husain et al., 2007) 
Loevgren et al. (2007) initiated a study to examine the prevalence and 
severity of symptoms and difficulties with functioning in women and men with 
inoperable lung cancer.  The study looked at these issues at three points close to 
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diagnosis, the extent to which these issues change over time, and patient 
characteristics that influence these issues.  Loevgren et al. (2007) analyzed data 
generated from 159 patients, 70 women and 89 men, who had completed the 
EORTC QLQ-C30+ Lung Cancer13 (LC13) at baseline (T1), 1 month (T2), and 3 
months (T3) after T1.  
The EORTC QLQ-C30 + LC13 is a self-report health-related QOL 
instrument that assesses general aspects of health-related QOL through 30 
items consisting of five functional scales, three symptom scales, a global health 
status/QOL scale, and several single items such as dyspnea and insomnia.  The 
LC13 module assesses disease-specific symptoms, treatment-related side 
effects, and pain medication.  Each item is evaluated on a four-point Likert scale 
except for the global health status/QOL items and these have responses that 
range from “very poor” to “excellent”.  However, the global health/QOL scale was 
not used in this study (Loevgren, 2007). 
The study revealed that the most prevalent symptoms and difficulties with 
functioning were associated with fatigue at all time points for both women and 
men.  However, significantly more women than men reported “feeling tense”, 
“worried”, “depressed” and more limited in work/daily activities at baseline and 
also reported that at T1, their physical condition or treatments interfered with their 
social activities and at T3, they needed to stay in the bed or in a chair for most of 
the day.  One limitation of this study was the small sample size, but it is difficult to 
accrue a large sample of lung cancer patients to these studies as this group is 
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typically severely ill and non-random attrition and non-participation is a significant 
barrier to accrual (Loevgren et al., 2007). 
Fatigue Assessment 
Regarding routine assessment of fatigue by clinicians, several studies 
have sought to identify potential barriers from the patient, clinician, and system 
perspectives.  In 2002, Passik et al. conducted a clinical trial to explore patient-
related barriers to communication about fatigue according to the patient 
perspective.  The study recruited 200 subjects equally from multiple urban and 
rural sites in the Community Cancer Care, Inc. network in Indiana.  The 
investigators utilized the 28-item self-report Fatigue Management Barriers 
Questionnaire (FMBQ) and found that 46.7% of the subjects reported that 
interventions for fatigue were not being offered as well as 43.1% stated that they 
were unaware of any possible treatments for fatigue.  This led the investigators to 
conclude that physicians and patients seem to have reservations discussing 
fatigue as a symptom of the disease and as a consequence of therapy.      
Borneman et al. (2007) reported data on the phase one portion of a three 
phase five year prospective National Cancer Institute (NCI) - funded clinical trial 
seeking to translate the National Comprehensive Cancer Network (NCCN) 
Cancer-Related Fatigue Clinical Practice Guidelines in Oncology into practice 
and construct a translational interventional model that can be reproduced across 
other settings.  Phase one of the study examined fatigue-related patient, 
professional, and system barriers that hinder routine use of NCCN guidelines 
recommendations. 
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The trial recruited 69 patients with a known diagnosis of breast, lung, 
colon or prostate cancer from one medical oncology adult ambulatory care clinic 
at a NCI-designated comprehensive cancer center in Southern California.  A 
chart audit was conducted to evaluate practitioner practices.  The audit revealed 
a lack of adherence to guidelines, documentation of fatigue, and referrals for 
supportive care.  Of note, the greatest adherence was documented for 
assessment of anemia at 28.99%.  A significant number of the patients (66%) 
reported that they had never discussed their complaints of fatigue with their 
physician and the prevailing belief (54%) was if fatigue was important, then the 
physician would have initiated conversation on this subject.  (Borneman et al., 
2007) 
Knowles et al. (2000) conducted a survey study of registered nurses 
working with the Department of Clinical Oncology at the Cancer Centre in 
Edinburgh, UK.  The investigators wished to evaluate nurses’ knowledge of 
fatigue, assessment practices, and what interventions they employed to address 
patient complaints of fatigue.  The study revealed that cancer-related fatigue was 
identified as a common symptom experienced by a majority of the patients the 
respondents cared for and 75% of the respondents reported that they assessed 
for fatigue in their patient population.  However, the study did not delineate the 
methods and depth of fatigue assessment and whether assessment of fatigue 
was routinely performed.  Of note, nurses utilizing common grading criteria were 
more likely to work with patients enrolled on clinical trials.   
Summary 
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From the review of literature, many of the studies exploring fatigue, 
symptom distress, and impact on quality of life in women with lung cancer 
specifically were conducted in the 1990s, and the state and rigor of treatment 
modalities, even palliative, has changed since that time.  The majority of current 
studies examining this population have largely not been conducted in the United 
States so results are not necessarily generalizable to our population of women 
who may have different roles and concerns.  Sufficient studies exist to explore 
the issue of fatigue and quality of life in the general lung cancer population, 
however, most of the participants in these trials were men, rendering the results 
not clearly applicable to women.  Loevgren et al. (2007) speculates that a lack of 
knowledge about differences in symptom experiences between men and women 
may impede appropriate intervention from the health care system.  Also noted, 
was a lack of trials with any interventions to address fatigue and thereby impact 
quality of life in this patient population. 
Studies suggest that there are many barriers that hinder systematic 
assessment, management, and documentation of cancer-related fatigue.  In an 
effort to breakdown these barriers, further studies of the patterns of clinician and 
nursing assessment of fatigue need to be completed. 
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Chapter Three 
Methods 
The purpose of this study was to measure fatigue levels, characterize the 
fatigue experience, and assess for gender differences in perceptions of fatigue 
and quality of life (QOL) in patients with advanced lung cancer receiving 
chemotherapy.  The secondary purpose of this study was to examine practice 
patterns in the ambulatory setting regarding the routine assessment of fatigue.  
This chapter delineates the sample, measurement tools, and procedures utilized 
to facilitate obtaining the information sought by the researcher.  The chapter ends 
with a description of data analysis. 
Setting and Sample 
This study was a secondary analysis of a larger study that was already 
underway in the ambulatory care clinics of a large, National Cancer Institute-
designated comprehensive cancer center.  This larger study had accrued over 
300 patients at the time of this study and sought to examine the impact and 
relationships of stress management and exercise training on QOL during 
chemotherapy treatment.  Data on fifty subjects, 25 women and 25 men, all with 
advanced lung cancer, was extracted and examined to achieve a representative 
sample of each gender to assess for any differences in fatigue severity, 
frequency, total interference and QOL.  Participants were 18 years of age or 
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older; capable of speaking and reading standard English; diagnosed with 
advanced lung cancer; had not received intravenous chemotherapy 
administration in the last two months; were scheduled to receive cytotoxic 
chemotherapy as outpatients at the center over a period of at least 14 weeks; 
had an ECOG performance status of zero, one, or two; and were able to provide 
informed consent.     
Instrumentation 
 Short-Form 36® (SF-36) Acute Version 1 
The SF-36 is a multi-purpose, short-form health survey questionnaire 
consisting of 36 items.  It is a self-report measure designed to assess perceived 
health and functioning and contains eight scales: ten physical functioning items, 
two social functioning items, four role limitations due to physical problems items, 
three role limitations due to emotional problems items, five mental health items, 
four energy and vitality items, two pain items, and five general perceptions of 
health items.  Each scale uses a variety of rating formats and raw scores are 
converted to a standard metric.  Subjects provide Likert-type responses to 
questions regarding perceived ability to complete activities of daily living.  Each 
item is scored on a scale from 0 to 100 with 0 representing the worst possible 
health state and 100 representing the best possible health state (Jenkinson et al., 
1993).  The interrelatedness of the psychosocial and functional dimensions of 
QOL is correlated with physical functioning, and psychosocial aspects are 
measured in terms of social activities and relationships (Losito et al., 2006) 
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Reliability and validity.  The SF-36 has subscale reliability coefficients 
ranging from 0.76 to 0.93.  Content validity and construct validity have been 
supported in multiple QOL studies (Ware et al., 2002; Losito et al, 2006) 
Fatigue Symptom Inventory (FSI) 
The FSI is a 14-item self-report tool that assesses the severity, frequency, 
and daily pattern of fatigue, as well as its perceived interference with 
performance.  Four items measure severity on separate 11-point scales that 
assess most, least, and average fatigue in the past week as well as current 
fatigue.  Frequency is measured utilizing two separate items that assess the 
number of days in the past week that fatigue was felt as well as the extent of 
each day on average fatigue was felt.  Perceived interference is measured on 
seven separate 11-point scales that assess the degree to which fatigue in the 
past week was judged to interfere with general level of activity, ability to bathe 
and dress, normal work activity, ability to concentrate, relations with others, 
enjoyment of life, and mood.  Interference ratings can be added to obtain a total 
perceived interference score.  The final item is a diurnal variation measured 
using a single item that provides descriptive information about daily patterns of 
fatigue (Jacobsen, 2004). 
Reliability and validity.  The FSI is an established reliable and valid 
measurement tool of fatigue in patients with cancer.  The Cronbach’s alpha 
coefficient ranges from 0.92 to 0.95, with convergent validity supported by 
significant correlations with the Profile of Mood States-Fatigue (POMS-F).  
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Construct validity was supported by significant correlations with life satisfaction 
and depression (Hann et al., 2000).  
Demographic Data Form 
Demographic data was gathered from existing self-report and medical 
record review information collected during enrollment of the subjects.  Data 
extracted for this study included age, gender, histology, stage of disease, ECOG 
status, whether treatment included radiotherapy and/or biologic therapy, previous 
chemotherapy, marital status, ethnicity, race, educational status, employment 
status, occupations of both subject and spouse, and net household income.  
Chart Audit Form 
A chart audit form was developed to track provider assessment and 
documentation of fatigue levels for the 50 subjects examined in this study.   Also, 
method of assessment utilized was assessed.  Charts were reviewed for use of 
any of the five most common tools of fatigue level assessment:  a four-point 
verbal rating scale (none, mild, moderate, severe); a five-point verbal rating scale 
(none, mild, moderate, severe, very severe); an eleven-point numeric scale (0 is 
no fatigue and 10 is worst possible fatigue); a four-point numeric scale (Common 
Toxicity Criteria of the National Cancer Institute); and a 10cm visual analogue 
scale (no fatigue to worst possible fatigue).  If present in the documentation, data 
was appropriately recorded. 
Institutional Approvals 
Approval to conduct the larger study had already been obtained from the 
Scientific Review Committee (SRC) of the institution from which the subjects 
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were accrued and the University of South Florida Institutional Review Board 
(IRB).  Both entities are in existence to evaluate the validity of a study and to 
protect the welfare of any human subjects who chose to participate in this study.  
An amendment to the original study was drafted to include the chart audit that 
assessed provider practice patterns of assessment and documentation of fatigue 
levels and was approved by the University of South Florida IRB.   
Procedures 
With assistance from the researchers conducting the larger study, the 
existing database was queried for an equal number of female and male subjects 
with advanced lung cancer who had received at least one cycle of chemotherapy.  
The subjects’ FSI and SF-36 questionnaire scores at 5 to 6 weeks after a single 
cycle of chemotherapy, as well as pertinent demographic data, were gathered.  
Also, the medical record was reviewed for physician and nurse documentation of 
fatigue levels and methods of assessment on the baseline office visit and the first 
follow-up visit after a single cycle of chemotherapy.    
Data Analysis 
Descriptive statistics were used to analyze the demographic data including 
frequencies, percentages, means, and standard deviations.  Gender differences 
in fatigue levels and QOL scores were analyzed for statistical significance 
utilizing t-tests.   Categorical data regarding the absence or presence of fatigue 
assessment by the physician and nurse was analyzed utilizing frequencies and 
percentages. 
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Chapter Four 
Results, Discussion and Conclusions 
 This chapter presents the findings of the study.   Included in this chapter 
are the results, discussion of the findings and limitations, conclusions, and 
recommendations for future research. 
Results 
 The sample consisted of 50 total subjects, 25 women and 25 men. They 
ranged in age from 40 to 80 with a mean age of 62.4 (SD=10.1).  Of the sample, 
64 percent were married and 30 percent were divorced.  The majority of the 
participants were white, representing 48 of 50 patients.  Nearly half of the 
subjects reported some college education or specialized training while a quarter 
reported a high school graduate level of education (Table 1).   
Table 1 
Frequency and Percent of Sample Demographic Characteristics 
 
Variable Frequency Percent 
 
Male 
 
25 
 
50.0 
 
Gender 
Female 
 
25 50.0 
Currently 32 64.0 
Divorced 15 30.0 
Never 2 4.0 
Marital Status 
Widowed 
 
1 2.0 
White 48 96.0 
Black/African American 1 2.0 
Race 
More Than 1 Race 
 
1 2.0 
Partial High School (10th & 11th) 2 4.0 
High School Graduate 12 24.0 
Partial College or Special Training 21 42.0 
College or University Grad 8 16.0 
Education 
Graduate Degree 7 14.0 
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The majority (n=22) of subjects were retired.  Household incomes were 
fairly evenly distributed across a range from $20,000 up to greater than 
$100,000, with nine patients preferring not to respond to this particular 
demographic question (Table 2).   
Table 2 
Frequency and Percent of Employment Status and Household Income 
 
Variable                     Frequency                     Percent                            
 
Retired 
 
22 
 
44.0 
Full-time Job 7 14.0 
Part-time Job 6 12.0 
On leave w/ pay 6 12.0 
On leave w/o pay 5 10.0 
 
Employment 
Disabled 
 
4 8.0 
Less than $10,000 5 10.0 
$10,000-$19,999 4 8.0 
$20,000-$39,999 10 20.0 
$40,000-$59,999 6 12.0 
$60,000-$100,000 9 18.0 
> $100,000 7 14.0 
Household 
Income 
Prefer Not to Answer 9 18.0 
 
 All of the subjects in this sample had lung cancer (n=50).  Of the 50, 26 
patients had Stage IV non-small cell lung cancer, 14 had stage III non-small cell 
lung cancer, five had limited stage small cell lung cancer, and five had extensive 
stage small cell lung cancer.  Approximately one-third of the patients had an 
ECOG performance status of 0 and two-thirds had an ECOG of one.  The 
majority of patients were receiving chemotherapy alone, with only nine receiving 
radiation in addition to chemotherapy and nine receiving biotherapy in addition to 
chemotherapy.  Forty-five subjects had never had chemotherapy before while 
five had prior chemotherapy experience (Table 3). 
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Table 3 
Frequency and Percent of Disease and Planned Concurrent Therapy 
 
 Variable               Frequency              Percent 
 
Type of Ca 
 
 
Lung 
 
50 
 
100.0 
1 32 64.0 ECOG PS 
0 
 
18 36.0 
IV NSCLC 26 52.0 
III NSCLC 14 28.0 
Stage 
Ltd. SCLC 5 10.0 
 Ext.SCLC 5 10.0 
Receiving Radiation Yes 
 
9 18.0 
Receiving Biotherapy Yes 9 18.0 
Previous Chemotherapy Yes 5 10.0 
 
Fatigue Symptom Inventory (FSI) 
 Levels, severity, frequency, and total interference of fatigue were 
assessed utilizing the FSI self-report questionnaire. Overall fatigue was reported 
with a mean of 5.9 (SD=3.0) for the highest level in the past week and a mean of 
2.1 (SD=1.9) for the lowest level in the past week.  Subjects reported that fatigue 
occurred with a mean of 4.7 days in the past seven days.  Fatigue was reported 
to have been present at a mean of 4.5 hours (SD=3.1) per day (Table 4).   
Men reported the highest level of fatigue with a mean score of 6.4 
(SD=3.1) and the lowest level with a mean of 2.4 (SD=2.0) in the week preceding 
the completion of the questionnaire.  Women reported the highest level of fatigue 
with a mean score of 5.4 (SD=3.0) and the lowest level with a mean of 1.9 
(SD=1.7).  Frequency data revealed that out of one week, men reported fatigue 
with mean scores of 4.8 days and women with mean scores of 4.6 days (Table 
4).   
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The overall, total interference scores revealed a mean of 20.3 (SD=19.9).  
The rate that fatigue interfered with levels of activity was reported as a mean of 
3.9 (SD=3.7).  Fatigue interfered with enjoyment of life with mean scores of 3.3 
(SD=3.1) and with enjoyment of life with reported mean scores of 3.3 (SD=3.1).  
Among the gender specific interference scores, fatigue interfered the most with 
levels of activity with a mean of 4.4 (SD=4.3) in men and a mean of 3.3 (SD=3.0) 
in women.  Fatigue interfered least with ability to bathe and dress self with men 
reporting a mean of 1.5 (SD=3.0) and women reporting a mean of 1.0 (SD=1.3) 
(Table 5). There were no significant differences in scores between women and 
men.    
Table 4  
 Means and Standard Deviations (SD) with Independent t-test Comparison of Severity and Frequency Items 
on the FSI Questionnaire 
  
Fatigue in past week  mean SD        t   p 
 
Overall 
 
5.9 
 
3.0 
  
Male 6.4 3.1 
 
Highest level 
 
 
  
Female 5.4 3.0 
1.212 .231 
Overall 2.1 1.9   
Male 2.4 2.0 
Lowest level  
 
 
 
Female 1.9 1.7 
  .981 .332 
Overall 4.0 2.5   
Male 4.4 2.6 
Average level 
 
 
  
Female 3.6 2.3 
1.192 .239 
Overall 3.0 2.7   
Male 3.6 3.1 
Level now 
 
 
 
Female 2.5 2.2 
     1.430 .160 
Overall 4.7 2.5   
 
Male 4.8 2.6 
How many days 
 
 
 
 
Female 4.6 2.5 
       .279 .782 
Overall 4.5 3.1   
Male 5.2 3.3 
How much of the day on average  
Female 3.8 2.7 
     1.544 .130 
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Table 5   
Means and Standard Deviations (SD) with Independent t-test Comparison of Interference Items on the FSI 
Questionnaire 
         
Fatigue in past week                                  Mean         SD            t         p 
 
Overall 
 
3.9 
 
3.7 
  
Male 4.4 4.3 .274 
 
Rate interfered with level of activity 
 
Female 3.3 3.0 
1.107 
.275 
Overall 1.2 2.3   
Male 1.5 3.0 .393 
Rate interfered with ability to bathe and dress 
self 
 
 
Female 1.0 1.3 
  .862 
.395 
Overall 3.6 3.5   
Male 3.8 3.9 .688 
Rate interfered with normal work activity 
 
 
 
Female 3.4 3.1 
  .404 
.688 
Overall 2.7 3.1   
Male 3.0 3.4 .503 
Rate interfered with ability to concentrate 
 
 
 
Female 2.4 2.8 
  .675 
.503 
Overall 2.5 3.0   
Male 3.0 3.4 .267 
Rate interfered with relations with other people 
 
 
 
Female 2.0 2.6 
1.122 
.268 
Overall 3.3 3.1   
Male 3.9 3.6 .195 
Rate interfered with enjoyment of life 
 
 
 
Female 2.8 2.6 
1.313 
.196 
Overall 3.0 3.2   
Male 3.6 3.7 .288 
Rate interfered with mood 
Female 2.6 2.5 
1.075 
.288 
 
Short-Form-36 (SF-36) 
 Quality of life was measured utilizing the SF-36 health survey instrument.  
Overall physical functioning revealed a mean score of 54.9 (SD=29.7).  The 
overall mean score for physical role limitations was 34.5 (SD=42.2) and vitality 
35.1 (SD=24.2).  Both were below the midpoint indicating lower states of health.  
The remaining mean scores were nearing or above the midpoint indicating 
average to better states of health (Table 6). 
Again, no significant gender differences were noted in quality of life 
measures.  Lower scores on this instrument represent a worse state of health 
and higher scores represent a better state of health.  Overall, physical functioning 
                                                                                                     
 
 
33
was the most affected of the eight domains measured by the SF-36.  Men 
reported mean scores of 48.6 (SD= 31.2), while women reported mean scores of 
61.2 (SD=27.2).  Of the eight scales, bodily pain was reported similarly among 
this sample with a reported mean score of 69.5 (SD=31.1) in men and 69.9 
(SD=26.0) in women (Table 6).  Of note, women reported better states of health 
than men, but this did not prove to be statistically significant upon analysis. 
Table 6 
Means and Standard Deviations (SD) with Independent t-test Comparison of Items on the SF-36 
Questionnaire  
Variable Mean SD            t    p 
 
Overall 
 
54.9 
 
29.7 
  
Male 48.6 31.2 
 
Physical Functioning 
 
 
 
Female 61.2 27.2 
-1.522 .135 
Overall 34.5 42.2   
Male 31.0 41.0 
Role Limitations – Physical 
Female 38.0 44.0 
  -.582 .563 
Overall 68.7 42.8   
Male 62.7 45.5 
Role Limitations – Emotional 
Female 74.7 40.0 
   -.991 .327 
Overall 35.1 24.2   
Male 30.8 23.9 
Vitality 
 
 
 
Female 39.4 24.2 
-1.265 .212 
Overall 72.0 24.2   
Male 68.0 29.8 
Mental Health 
 
 
 
Female 76.0 16.5 
-1.174 .246 
Overall 64.0 29.2   
Male 59.0 31.1 
Social Functioning 
 
 
 
Female 69.0 26.8 
-1.217 .230 
Overall 69.7 28.4   
Male 69.5 31.1 
Bodily Pain 
 
 
 
Female 69.9 26.0 
  -.049 .961 
Overall 45.9 19.3   
Male 43.7 18.2 
General Health 
Female 48.1 20.4 
  -.815 .419 
 
Chart Audit Form 
 For each of the 50 subjects, physician and nursing documentation was 
reviewed at baseline visit and at first visit after chemotherapy for documentation 
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of presence of fatigue and method utilized to assess and define fatigue.  
Physician documentation of fatigue was noted to occur at a rate of 33% and 
nurses at a rate of 21%.  The two tools employed by practitioners to assist in 
screening for fatigue were the four-point verbal rating scale and the four-point 
numeric scale.    
Discussion 
Demographic Data 
 Data on the subjects was extracted from a much larger study currently 
being conducted in the ambulatory care clinics of a large, National Cancer 
Institute-designated comprehensive cancer center.   The sample consisted of an 
equal number of middle-class, white women and men.  All of the participants had 
advanced lung cancer and were receiving chemotherapy.  Few of the subjects 
were receiving concurrent radiation therapy or biotherapy so the results are not 
reflective of more vigorous therapy.  Also, few of the patients had received prior 
chemotherapy so the results are not generalized to those patients who have 
received other lines of therapy. 
 All of the subjects participating on the study had an ECOG PS of zero or 
one.  An ECOG PS of zero indicates no symptoms and a one indicates minimal 
symptoms.  The study prohibited patients with an ECOG performance status of 
greater than two from participating.  Many patients with advanced stages of lung 
cancer and a Performance Status two are eligible for palliative chemotherapy 
and likely the results are not representative of fatigue levels and quality of life in 
this population.  The sample was small, predominantly white and gathered from a 
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single geographic area; thus, results may not be generalizable beyond this 
sample. 
Fatigue Symptom Inventory (FSI) 
 Although the results of this study did not reveal a statistical significance in 
the severity, frequency, interference, or patterns of fatigue scores among the 
male and female participants, it did reveal some important findings.  For the 
highest level of fatigue in the past week, men and women reported moderate 
levels of fatigue.  Men and women reported fatigue on nearly 5 out of 7 days in 
the past week.  Fatigue, in both genders, interfered mostly with activity levels.   
Male participants scored the 14-item fatigue measures consistently higher 
than female participants.  The rate that fatigue interfered with enjoyment of life in 
the past week item revealed a mean score of 3.9 (SD=3.6) for the male subjects 
versus 2.8 (SD=2.6) for the female subjects.  The rate that fatigue interfered with 
relationships with other people and with mood in the past week showed mean 
scores of 3.0 (SD=3.4) and 3.6 (SD=3.7) for the male participants respectively, 
while the mean scores for the female participants were 2.0 (SD=2.6) and 2.6 
(SD=2.5) respectively.  
A limitation of this study was that fatigue was measured after the 
completion of a single cycle of chemotherapy.  Fatigue tends to be cumulative 
over the course of multiple cycles of chemotherapy.  The scores derived in this 
study are likely not reflective of the severity, frequency, interference and patterns 
of fatigue patients experience with receiving more than one cycle of 
chemotherapy.  Also, a majority of the patients on the study were receiving 
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chemotherapy alone and for those receiving concurrent radiation therapy or 
biotherapy, fatigue may be amplified.      
SF-36   
Overall, the subjects reported average to better states of health on the 
items of this measurement tool.  Physical role limitations and vitality scores were 
reported below midpoint and indicated perceived lesser states of health. 
The study results did not confirm statistically significant gender differences 
in quality of life measures.  Again, male participants scored all items of the SF-36 
lower than female participants.  Physical functioning appeared to affect health 
scores in men more so than women.  Men and women reported similar states of 
health for the physical role limitations and bodily pain items.  Both reported states 
of health below midpoint for physical role limitations and states of health above 
midpoint in relation to effect of bodily pain.     
Fatigue assessment 
 As fatigue is the most prevalent and most distressing symptom reported 
by advanced lung cancer patients, the need for consistent assessment is 
imperative.  There are well-established interventions to address the issue of 
fatigue in cancer patients.  Interventions to impact or alleviate fatigue cannot be 
employed if fatigue is not assessed.  Significant fatigue can lead to patients 
suffering in silence or ceasing therapy prematurely.   
While assessment of fatigue may be routinely performed by practitioners 
during office visits, the documentation examined in this study does not reflect this 
practice.  Physicians did document patients’ reports of fatigue more often than 
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nurses; however, rates of documentation were still quite low.  Both practitioners 
utilized the four- point verbal rating scale more frequently than other methods of 
fatigue assessment.  Several nurses utilized the four-point numeric rating scale; 
however, it should be noted that many of the subjects were on a concurrent 
chemotherapy trial and data in this format was required to document toxicities.  It 
is unknown, since symptoms tend to occur in clusters, if other symptoms such as 
pain or nausea and vomiting supersede the assessment and documentation of 
fatigue in daily practice.  The sample examined was small and all the subjects 
were recruited from a single ambulatory clinic. 
Implications for Nursing 
 Fatigue and quality of life (QOL) are critical concepts for nurses to seek to 
understand.  Although this study did not establish statistically significant gender 
differences in fatigue and QOL, it did reveal that fatigue is a problem for 
advanced lung cancer patients and that QOL is impacted.  In an effort to better 
support and treat these patients, nurses should be assessing for the presence of 
fatigue and incorporating possible interventions into nursing plans of care.  Also, 
timely assessment of fatigue and subsequent intervention may assist patients in 
complying with treatment plans and lessen the incidence of cessation of therapy 
due to intolerable toxicity in the form of fatigue. 
 Provider assessment of fatigue was inconsistently and poorly documented 
in this study.  In order to develop interventions to assist advanced lung cancer 
patients with fatigue and impact QOL, nurses must assess for the presence of 
the symptom first.  Barriers to assessment of fatigue must be addressed and 
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scales that assist in more consistent assessment and documentation of fatigue 
must be developed. 
Conclusions 
 No statistically significant gender differences were noted in the levels, 
severity, frequency or interference of fatigue in the sample utilized in this study.  
Also, no statistically significant gender differences were noted in quality of life 
measures.  Although there were some trends toward differences in men and 
women with advanced lung cancer, no significant differences were found.  A 
larger sample may reveal a statistical difference which would confer the need to 
be aware of this difference when applying interventions to address fatigue.  As 
fatigue has been shown to be a prevalent and distressing symptom in advanced 
lung cancer patients, it is important that as many facets of this issue are explored 
and documented by practitioners.  For the established interventions to assist in 
addressing fatigue and the many implications its presence has and to generally 
better serve these patients, assessment and subsequent documentation of 
fatigue levels must occur.  
Recommendations for future research 
 Since the data from this study revealed that there was no difference in 
reported fatigue levels and quality of life levels between men and women, future 
studies should be conducted with larger sample sizes to determine if there exists 
a statistical significance.  Future studies should also seek to accrue a more 
racially diverse sample.  Expanding the exploration of practitioner assessment of 
fatigue is imperative and should occur in multiple settings to truly establish 
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pattern.  Further studies as to the actual and perceived barriers to fatigue 
assessment and documentation by practitioners are imperative.  
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Appendix A:  Chart Audit Form 
 
    
Patient Screened for 
Presence and 
Severity of Fatigue? Method or Tool Utilized to Screen? 
Subject 
Number 
Date of 
Visit Physician Nurse 
4 point 
verbal 
rating 
scale 
5 point 
verbal 
rating 
scale 
11 point 
numeric 
scale 
4 point 
numeric 
scale 
10cm 
visual 
analogue 
scale 
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Appendix B:  Medical Chart Review Form 
 
ID __ __ __ 
 
GENDER 0 Male       1 Female 
 
HEIGHT  __ __ __  inches 
 
WEIGHT  Pre-chemo weight:  __ __ __  lbs. 
 
GROUP   1 UCO  2 SM  3  EX  4 SMEX 
        
DXDATE  Date of initial diagnosis for cancer (physician approval date):  __ __ / __ __ / __ __ __ 
__ (mm/dd/yy) 
  
RCDATE  Date of diagnosis of cancer recurrence requiring current chemo:  __ __ / __ __ / __ __ 
__ __ (mm/dd/yy) 
 
CATYPE  Cancer type  __ __ 
  
1. Adrenal 16. Liver  
2. Bladder 17. Lung 
31. Sarcoma, not 
osteosarcoma 
 
32. Squamous Cell  3. Bone (e.g., 
osteosarcoma) 33. Testicular  
4. Breast 
18. Lymphoma (Hodgkins, 
NHL, Mycosis Fungoides) 
34. Thyroid  
5. Brain 19. Melanoma  
6. Carcinoid (GI) 20. Merkle Cell 
35. Unknown Primary 
 
7. Cervical 21. Mesothelioma 36. Uterine  
8. Colon 22. Multiple Myeloma 37. Vaginal/Vulvar  
9. Endometrial 23. Nasal & Sinus 88. Other:  
10. Esophageal 24. Pharyngeal   
11. Gastric (Stomach) 25. Neuroblastoma   
12. Kidney 26. Ovarian   
13. Layrnx 27. Pancreatic   
28. Prostate   14. Leukemia (ALL,  
AML, CLL, CML) 29. Rectal/Anal   
15. Lip & Oral cavity 30. Salivary   
 
CATYPE2  Does patient have a second cancer diagnosis?        If yes, enter code from list: __ __  
 If no, leave blank. 
   
STAGE  Stage at start of chemo: ___  1  Stage I 
     (Check one)   ___  2  Stage II 
___  3  Stage III 
___  4  Stage IV 
___  5  Limited Stage SCLC 
___  6  Extensive Stage SCLC 
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Appendix B:  (Continued) 
 
ECOG0  Pre-Chemo ECOG Performance Status (check one): 
 
 
___  0 Fully active, able to carry on all pre-disease performance without restriction 
___  1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a 
light or sedentary nature, e.g., light housework, office work 
___  2 Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and 
about more than 50% of waking hours 
___  3 Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours 
___  4  Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair 
 
Surgery 
 
SURG1D  Most recent surgery date:  __ __ / __ __ / __ __ __ __ (mm/dd/yy) 
 
SURG2D  Previous surgery date:  __ __ / __ __ / __ __ __ __ (mm/dd/yy) 
 
SURG3D  Previous surgery date:  __ __ / __ __ / __ __ __ __ (mm/dd/yy) 
 
 
Radiation Therapy 
 
XRTC  XRT while on study:  No 0    Yes 1 
 
 XRTCTX  Number of XRT treatments while on study:  __ __ 
 XRTCDS  Total dose of XRT while on study: __ __ __ __ 
 XRTCSD  Date of first Tx on study: __ __ / __ __ / __ __ __ __   (mm/dd/yy) 
 XRTCED  Date of last Tx on study:  __ __ / __ __ / __ __ __ __   (mm/dd/yy) 
 
XRTP1  XRT prior to current chemo (most recent previous course):    No 0  Yes 1 
  
 XRTP1TX  Number of treatments during this course:  __ __ 
 XRTP1DS  Total dose of XRT during this course:  __ __ __ __ 
 XRTP1SD  Tx Start Date:  __ __ / __ __ / __ __ __ __   (mm/dd/yy) 
 XRTP1ED  Tx End Date:  __ __ / __ __ / __ __ __ __   (mm/dd/yy) 
 
XRTP2 XRT prior to current chemo (course before most recent previous course):   No 0            
Yes 1 
 
 XRTP2TX  Number of treatments during this course:  __ __ 
 XRTP2DS  Total dose of XRT during this course:  __ __ __ __ 
 XRTP2SD  Tx Start Date: __ __ / __ __ / __ __ __ __   (mm/dd/yy) 
 XRTP2ED  Tx End Date:  __ __ / __ __ / __ __ __ __   (mm/dd/yy) 
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Appendix B:  (Continued) 
Concurrent Hormone Treatment 
 HORTX1  Hormone treatment while on study:   No 0             Yes 1 
HORTXTY1  Type of hormone treatment: ___  0  None  
        ___  1  Tamoxifen (Nolvadex) 
       ___  2  Megestrol (Megase) 
       ___  3  Leuprolide (Lupron) 
       ___  4  Gosarelin (Zoladex) 
       ___  5  Medroxyprogesterone (Provera) 
___  6  Triptorelin (Trelstar) 
___  7  Anastrozole (Armidex) 
___  8  Femara (Letrozole) 
 
HORSD1  Date of first Tx while on study: __ __ / __ __ / __ __ __ __   (mm/dd/yy) 
HORED1  Date of last Tx while on study:  __ __ / __ __ / __ __ __ __   (mm/dd/yy) 
 
 
 HORTX2  Hormone treatment while on study:   No 0             Yes 1 
 
Concurrent Biological Treatment 
 BIOTX  Biological treatment while on study:   No 0             Yes 1 
BIOTXTY  Type of biological treatment:       ___  0  None 
          ___  1  Herceptin (Trastuzumab) 
                    ___  2  BCG (Bacillus Calmete-Guérin)  
     
   
BIOSD  Date of first Tx while on study: __ __ / __ __ / __ __ __ __   (mm/dd/yy) 
BIOED  Date of last Tx while on study:  __ __ / __ __ / __ __ __ __   (mm/dd/yy) 
 
 
Previous Chemotherapy 
 
PRVCHM  Did patient receive chemo prior to the current chemo? No 0  Yes 1 
 
PRVCHMX  How many prior courses of chemo did patient receive?  __ __ 
(a course refers to a uniform prescription of chemotherapeutic drugs administered over a 
series of cycles, usually 21 day cycles) 
CHM1  Chemo prior to current chemo (most recent previous course): No 0     Yes 1 
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Appendix C:  Demographic Form 
 
GBI 
1. Today's date:   /  /  (MM/DD/YYYY) 
2. Birth date:   /  /  (MM/DD/YYYY) 
 
3a. Ethnic group (check one): 
Hispanic/Spanish/Latino         
Not Hispanic/Spanish/Latino  
 
3b. Racial Background (check one): 
American Indian or Alaskan Native 
Asian 
Black or African American 
More than one race (specify): 
Native Hawaiian/Pacific Islander 
White 
 
4. Marital status (check one): 
Never married 
Currently married 
Separated 
Divorced 
Widowed 
 
5a. Current living arrangement (check one box): 
Live alone 
Live with spouse/partner 
Live with spouse/partner and children 
Live with children (no spouse/partner) 
Live with roommate who is not partner 
Live with parents 
Other (specify): 
 
5b. Number of children living at home (enter 0 if none): 
 
6. How long in current living arrangement (check one): 
Less than 1 month 
One to 6 months 
Seven months to less than 2 years 
Two to 5 years 
More than 5 years 
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Appendix C:  (Continued) 
 
7. Level of school completed (check one): 
Less than 7th grade 
Junior High School (7th, 8th, & 9th grade) 
Partial High School (10th or 11th grade) 
High School graduate 
Partial college or specialized training 
College or university graduate 
Graduate professional training (graduate degree) 
 
8. Current employment situation (check the one box that applies the most): 
A. WORKING 
Full time at job 
Part time at job 
B. ON LEAVE 
On leave with pay 
On leave without pay 
C. NOT 
EMPLOYED 
Disabled 
Seeking work 
Retired 
Homemaker 
Student 
 
9. Which category best describes your usual occupation? If you are not currently 
employed, which category best describes your LAST job? (check one): 
Professional (e.g., teachers/professors, nurses, lawyers, physicians, & engineers) 
Manager/Administrator (e.g., sales managers) 
Clerical (e.g., secretaries, clerks, or mail carriers) 
Sales (e.g., sales persons, agents, or brokers) 
Service (e.g., police, cooks, waiters, or hairdressers) 
Skilled Crafts, Repairer (e.g., carpenters) 
Equipment or Vehicle Operator (e.g., truck drivers) 
Laborer (e.g., maintenance or factory workers) 
Farmer (e.g., owners, managers, operators, or tenants) 
Member of the military 
Homemaker (with no job outside the home) 
Other (please describe) 
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Appendix C:  (Continued) 
 
10. Which category best describes your spouse's usual occupation? If your spouse is not 
currently employed, which category best describes his/her LAST job? (check one): 
Do not have a spouse 
Professional (e.g., teachers/professors, nurses, lawyers, physicians, & engineers) 
Manager/Administrator (e.g., sales managers) 
Clerical (e.g., secretaries, clerks, or mail carriers) 
Sales (e.g., sales persons, agents, or brokers) 
Service (e.g., police, cooks, waiters, or hairdressers) 
Skilled Crafts, Repairer (e.g., carpenters) 
Equipment or Vehicle Operator (e.g., truck drivers) 
Laborer (e.g., maintenance or factory workers) 
Farmer (e.g., owners, managers, operators, or tenants) 
Member of the military 
Homemaker (with no job outside the home) 
Other (please describe) 
 
 
11. What is your approximate annual gross income? (check one)  
(Remember all information you provide will remain completely confidential) 
Less than $10,000 
$10,000 - $19,999 
$20,000 - $39,999 
$40,000 - $59,999 
$60,000 - $100,000 
Greater than $100,000 
Prefer not to answer 
 
12. Approximate annual gross income for your household: (check one box) 
(Remember all information you provide will remain completely confidential) 
Less than $10,000 
$10,000 - $19,999 
$20,000 - $39,999 
$40,000 - $59,999 
$60,000 - $100,000 
Greater than $100,000 
Prefer not to answer 
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Appendix D:  FSI Questionnaire 
 
FSI 
For each of the following, check one box next to the number that best 
indicates how that item 
applies to you. 
1. Rate your level of fatigue on the day you felt most fatigued during the past 
week: 
0  1  2  3  4  5  6  7  8  9  10 
Not at all         As fatigued 
Fatigued         as I could be 
 
2. Rate your level of fatigue on the day you felt least fatigued during the past 
week: 
0  1  2  3  4  5  6  7  8  9  10 
Not at all         As fatigued 
Fatigued         as I could be 
 
3. Rate your level of fatigue on the average during the past week: 
0  1  2  3  4  5  6  7  8  9  10 
Not at all         As fatigued 
Fatigued         as I could be 
 
4. Rate your level of fatigue right now: 
0  1  2  3  4  5  6  7  8  9  10 
Not at all         As fatigued 
Fatigued         as I could be 
 
5. Rate how much, in the past week, fatigue interfered with your general level of 
activity: 
0 1 2 3 4 5 6 7 8 9 10 
No          Extreme 
Interference         interference 
 
6. Rate how much, in the past week, fatigue interfered with your ability to bathe 
and dress yourself: 
0 1 2 3 4 5 6 7 8 9 10 
No          Extreme 
Interference         interference 
 
7. Rate how much, in the past week, fatigue interfered with your normal work 
activity (includes both work outside the home and housework): 
0 1 2 3 4 5 6 7 8 9 10 
No          Extreme 
Interference         interference 
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Appendix D:  (Continued) 
 
8. Rate how much, in the past week, fatigue interfered with your ability to 
concentrate: 
0 1 2 3 4 5 6 7 8 9 10 
No          Extreme 
Interference         interference 
 
9. Rate how much, in the past week, fatigue interfered with your relations with 
other people: 
0 1 2 3 4 5 6 7 8 9 10 
No          Extreme 
Interference         interference 
 
10. Rate how much, in the past week, fatigue interfered with your enjoyment of 
life: 
0 1 2 3 4 5 6 7 8 9 10 
No          Extreme 
Interference         interference 
 
11. Rate how much, in the past week, fatigue interfered with your mood: 
0 1 2 3 4 5 6 7 8 9 10 
No          Extreme 
Interference         interference 
 
12. Indicate how many days, in the past week, you felt fatigued for any part of 
the day: 
0 1 2 3 4 5 6 7 
Days       Days 
 
13. Rate how much of the day, on average, you felt fatigued in the past week: 
0  1  2  3  4  5  6  7  8  9  10 
None of         The entire 
the day         day 
 
14. Indicate which of the following best describes the daily pattern of your 
fatigue in the past week: 
0   1   2    3   4 
Not at all Worse in Worse in the Worse in the No consistent daily 
fatigued the morning afternoon evening pattern of fatigue 
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Appendix E:  SF-36 
 
1. In general, would you say your health is  
Excellent   Very good   Good   Fair   Poor 
 
2. Compared to one week ago, how would you rate your health in general now?  
 
Much better now than one week ago............. 
Somewhat better now than one week ago.... 
About the same............................................... 
Somewhat worse now than one week ago..... 
Much worse now than one week ago.............. 
 
3. The following items are about activities you might do during a typical day. Does your 
health now limit you in these activities? If so, how much? 
 
Yes, limited  Yes, limited  No, not 
a lot   a little   limited at all 
a. Vigorous activities, such as running, lifting 
heavy objects, participating in strenuous 
sports.................................................................. 
b. Moderate activities, such as moving a table, 
pushing a vacuum cleaner, bowling or playing 
golf......................................................................... 
c. Lifting or carrying groceries..................................... 
d. Climbing several flights of stairs.............................. 
e. Climbing one flight of stairs..................................... 
f. Bending, kneeling or stooping.................................. 
g. Walking more than a mile........................................ 
h. Walking several blocks............................................ 
i. Walking one block.................................................... 
j. Bathing or dressing yourself..................................... 
 
4. During the past week, have you had any of the following problems with your work or 
other regular dailyactivities as a result of your physical health? 
 
Yes  No 
 
a. Cut down the amount of time you spent 
on work or other activities................................................................. 
b. Accomplished less than you would like............................................ 
c. Were limited in the kind of work or other activities........................... 
d. Had difficulty performing the work or other activities 
(for example it took extra effort)........................................................ 
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Appendix E:  (Continued) 
 
5. During the past week, have you had any of the following problems with your work or 
other regular daily activities as a result of any emotional problems (such as feeling 
depressed or anxious)?  
Yes  No 
a. Cut down the amount of time you spent 
on work or other activities................................................................. 
b. Accomplished less than you would like............................................ 
c. Didn't do work or other activities as carefully as usual..................... 
 
6. During the past week, to what extent has your physical health or emotional problems 
interfered with your normal social activities with family, friends, neighbors, or groups?  
Not at all........................ 
Slightly........................... 
Moderately..................... 
Quite a bit...................... 
Extremely....................... 
7. How much bodily pain have you had during the past week?  
 
None..................... 
Very mild.............. 
Mild..................... 
Moderate............... 
Severe................... 
Very severe............. 
 
8. During the past week, how much did pain interfere with your normal work (including 
both work outside the home and housework)?  
 
Not at all........................ 
A little bit........................ 
Moderately..................... 
Quite a bit...................... 
Extremely....................... 
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Appendix E:  (Continued) 
 
9. These questions are about how you feel and how things have been with you during 
the past week. For each question, please give the one answer that comes closest to the 
way you have been feeling.  
 
All of       Most of  A good       Some of     A little of None  
the time   the time bit of the     the time      the time of the 
      time     time 
How much of the time  
during the past week: 
 
a. Did you feel full of pep?............. 
b. Have you been a nervous 
person?...................................... 
c. Have you felt so down in the 
dumps that nothing could cheer 
you up?........................................ 
d. Have you felt calm and 
peaceful?................................... 
e. Did you have a lot of energy?.... 
f. Have you felt downhearted and 
blue?.......................................... 
g. Did you feel worn out?............... 
h. Have you been a happy person? 
i. Did you feel tired?....................... 
 
10. During the past week, how much of the time has your physical health or emotional 
problems interfered with your social activities (like visiting with friends, relatives, etc.)?  
 
All of the time............... 
Most of the time........... 
Some of the time.......... 
A little of the time....... 
None of the time............ 
 
11. Please choose the answer that best describes how TRUE or FALSE each of the 
following statements is for you.  
 
      Definitely    Mostly   Not     Mostly     Definitely 
True        True    Sure      False        False 
 
a. I seem to get sick a little easier 
than other people.......................... 
b. I am as healthy as anybody I 
know.............................................. 
c. I expect my health to get worse.... 
d. My health is excellent................... 
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Appendix E:  (Continued) 
 
12. How much nausea have you had during the past week? (Check one) 
None..................... 
Very mild.............. 
Mild..................... 
Moderate............... 
Severe................... 
Very severe.......... 
 
13. During the past week, how much did nausea interfere with your normal work 
(including both work outside the home and housework)? (Check one) 
 
Not at all................. 
A little bit................ 
Moderately............. 
Quite a bit.............. 
Extremely............... 
